| 1 |
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Frances Alice Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu et al. · New England Journal of Medicine
Open access |
13 Jul 2005 |
5,471 |
| 2 |
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
Matthew David Hellmann et al. · New England Journal of Medicine
Open access |
28 Sep 2019 |
2,901 |
| 3 |
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
Luis G Paz-Ares et al. · The Lancet Oncology
|
18 Jan 2021 |
1,396 |
| 4 |
miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis
Carmen Elena Condrat, Dana Claudia Thompson, Mădălina Gabriela Barbu et al. · Cells
Open access |
23 Jan 2020 |
1,367 |
| 5 |
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Edward B. Garon et al. · The Lancet
Open access |
2 Jun 2014 |
1,321 |
| 6 |
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial
Luis G Paz-Ares, Filippo de Marinis, Mircea Dediu et al. · The Lancet Oncology
Open access |
16 Feb 2012 |
617 |
| 7 |
NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial
Sylvie Bonvalot et al. · The Lancet Oncology
Open access |
8 Jul 2019 |
537 |
| 8 |
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
Nick Thatcher, Fred R. Hirsch, Alexander Luft et al. · The Lancet Oncology
Open access |
4 Jun 2015 |
484 |
| 9 |
Global Retinoblastoma Presentation and Analysis by National Income Level
Global Retinoblastoma Study Group et al. · JAMA Oncology
Open access473 authors |
27 Feb 2020 |
382 |
| 10 |
Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study
Tudor–Eliade Ciuleanu, Lilia V. Stelmakh, Saulius Cicėnas et al. · The Lancet Oncology
|
29 Jan 2012 |
374 |
| 11 |
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
Luis G Paz-Ares et al. · Journal of Thoracic Oncology
Open access |
13 Oct 2021 |
326 |
| 12 |
Survival rates of patients with metastatic malignant melanoma.
Angela Sandru, Sebastian Voinea, Eugenia Panaitescu et al. · PubMed
Open access |
15 Feb 2016 |
290 |
| 13 |
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update
Martin Reck et al. · ESMO Open
Open access |
Oct 2021 |
192 |
| 14 |
Hormone Therapy in Breast Cancer
Mădălina Drăgănescu, Codruţa Carmocan · Chirurgia
Open access |
2017 |
151 |
| 15 |
MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors
Dan-Corneliu Jinga, Alexandru Blidaru, Ileana Condrea et al. · Journal of Cellular and Molecular Medicine
Open access |
Apr 2006 |
147 |
| 16 |
Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations
Georgios Tsaousis et al. · BMC Cancer
Open access |
3 Jun 2019 |
138 |
| 17 |
Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study
Luis G Paz-Ares et al. · The Lancet Oncology
Open access |
17 Feb 2015 |
134 |
| 18 |
Pharmacological and Therapeutic Properties of Punica granatum Phytochemicals: Possible Roles in Breast Cancer
Marius Moga, Oana Gabriela Dimienescu, Andreea Bălan et al. · Molecules
Open access |
17 Feb 2021 |
124 |
| 19 |
Endometriosis Associated Infertility: A Critical Review and Analysis on Etiopathogenesis and Therapeutic Approaches
Lidia Filip, Florentina Duică, Alina Prădatu et al. · Medicina
Open access |
9 Sep 2020 |
120 |
| 20 |
ESMO takes a stand on supportive and palliative care
Nathan I. Cherny, R. Catane, P. Kosmidis et al. · Annals of Oncology
Open access |
Sep 2003 |
118 |
| 21 |
Added value of Virtual Touch IQ shear wave elastography in the ultrasound assessment of breast lesions
Victor Ianculescu, Laura Ciolovan, Ariane Dunant et al. · European Journal of Radiology
|
6 Feb 2014 |
107 |
| 22 |
First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations
Luis G Paz-Ares et al. · Journal of Thoracic Oncology
Open access |
29 Oct 2022 |
105 |
| 23 |
Evidence for immune defects in breast and lung cancer patients
Iuliana Caraș, Alexandru Călin Grigorescu, Crina Stăvaru et al. · Cancer Immunology Immunotherapy
Open access |
4 Jun 2004 |
100 |
| 24 |
Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer
Joachim von Pawel, Jimmie Huling Harvey, David Robert Spigel et al. · Clinical Lung Cancer
|
3 Jan 2014 |
98 |
| 25 |
Role of microRNAs as Clinical Cancer Biomarkers for Ovarian Cancer: A Short Overview
Cristina Elena Staicu, Dragos Valentin Predescu, Călin Mircea Rusu et al. · Cells
Open access |
9 Jan 2020 |
90 |
| 26 |
Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial
Martin Reck et al. · European Journal of Cancer
Open access |
25 Aug 2024 |
87 |
| 27 |
XM02, the First Biosimilar G-CSF, is Safe and Effective in Reducing the Duration of Severe Neutropenia and Incidence of Febrile Neutropenia in Patients with Small Cell or Non-small Cell Lung Cancer Receiving Platinum-Based Chemotherapy
Ulrich Gatzemeier, Tudor–Eliade Ciuleanu, Mircea Dediu et al. · Journal of Thoracic Oncology
Open access |
21 May 2009 |
87 |
| 28 |
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1
Martin Reck et al. · Journal of Thoracic Oncology
Open access |
3 May 2023 |
78 |
| 29 |
Maternal HPV Infection: Effects on Pregnancy Outcome
Carmen Elena Condrat, Lidia Filip, Mirela Gherghe et al. · Viruses
Open access |
7 Dec 2021 |
75 |
| 30 |
Uniportal robotic-assisted thoracic surgery for lung resections
Diego González-Rivas, Mugurel Liviu Bosinceanu, Natalia Motaș et al. · European Journal of Cardio-Thoracic Surgery
Open access |
3 Aug 2022 |
74 |
| 31 |
A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma
Alba Ariela Brandes et al. · The Oncologist
Open access |
28 Sep 2018 |
70 |
| 32 |
Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand?
Fatma E. El‐Khouly et al. · Journal of Neuro-Oncology
Open access |
14 Sep 2019 |
69 |
| 33 |
Tyrosine kinase inhibitors in breast cancer (Review)
George Iancu, Dragoş Şerban, Cristinel Dumitru Badiu et al. · Experimental and Therapeutic Medicine
Open access |
3 Dec 2021 |
68 |
| 34 |
Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy
Simona Ruxandra Volovăț, Dragoş Viorel Scripcariu, Ingrid-Andrada Vasilache et al. · International Journal of Molecular Sciences
Open access |
18 Jan 2024 |
67 |
| 35 |
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial
David Paul Carbone et al. · Journal for ImmunoTherapy of Cancer
Open access |
Feb 2024 |
64 |
| 36 |
Evolution of radical mastectomy for breast cancer.
M Pleşca, Cristian Ioan Bordea, B El Houcheimi et al. · PubMed
Open access |
27 Mar 2017 |
63 |
| 37 |
Development of new immunotherapy treatments in different cancer types.
Dana Lucia Stănculeanu, Zob Daniela, Andreea Veronica Lazescu et al. · PubMed
Open access |
29 Mar 2017 |
60 |
| 38 |
Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial
Alexandru Călin Grigorescu, Ioana N. Draghici, Cornelia Niţipir et al. · Lung Cancer
|
Jul 2002 |
58 |
| 39 |
CD34—Structure, Functions and Relationship with Cancer Stem Cells
Petru Adrian Radu, Mihai Zurzu, Vlad Paic et al. · Medicina
Open access |
12 May 2023 |
57 |
| 40 |
The Effects of Capsaicin on Gastrointestinal Cancers
G Popescu, Cristian Scheau, Ioana Anca Bădărău et al. · Molecules
Open access |
28 Dec 2020 |
56 |
| 41 |
Pregnancy-Related Extracellular Vesicles Revisited
Carmen Elena Condrat, Valentin Nicolae Varlas, Florentina Duică et al. · International Journal of Molecular Sciences
Open access |
9 Apr 2021 |
55 |
| 42 |
Incidence of Retinoblastoma Has Increased: Results from 40 European Countries
Andrew W. Stacey et al. · Ophthalmology
Open access |
25 Jan 2021 |
55 |
| 43 |
Potential anticancer agents. XXVI. Spin Labelled Nitrosoureas
Ileana Baracu, Vasile Dobre, Ion Niculescu‐Duvaz · Journal für praktische Chemie
|
1985 |
55 |
| 44 |
The role of pro-fibrotic biomarkers in paroxysmal and persistent atrial fibrillation
Adina Elena Stanciu, Radu Gabriel Vatasescu, Marcel Stanciu et al. · Cytokine
|
8 Jan 2018 |
53 |
| 45 |
Quality, comparability and methods of analysis of data on childhood cancer in Europe (1978–1997): Report from the Automated Childhood Cancer Information System project
Eva Steliarova-Foucher, Peter Kaatsch, B. Lacour et al. · European Journal of Cancer
|
18 Aug 2006 |
53 |
| 46 |
G Protein-Coupled Receptors (GPCRs)-Mediated Calcium Signaling in Ovarian Cancer: Focus on GPCRs activated by Neurotransmitters and Inflammation-Associated Molecules
Dragos Valentin Predescu, Sanda Maria Creţoiu, Dragoş Crețoiu et al. · International Journal of Molecular Sciences
Open access |
7 Nov 2019 |
50 |
| 47 |
The Bidirectional Relationship between Pulmonary Tuberculosis and Lung Cancer
Mădălina Preda, Bogdan Cosmin Tănase, Daniela Zob et al. · International Journal of Environmental Research and Public Health
Open access |
10 Jan 2023 |
49 |
| 48 |
Plasma hormones in pre- and postmenopausal breast cancer
Denise Drafta, A. E. Schindler, St. M. Milcu et al. · Journal of Steroid Biochemistry
|
Jul 1980 |
49 |
| 49 |
Psoriasis Management Challenges Regarding Difficult-to-Treat Areas: Therapeutic Decision and Effectiveness
Alin Codruț Nicolescu, M Ionescu, María Magdalena Constantin et al. · Life
Open access |
7 Dec 2022 |
48 |
| 50 |
Final Safety and Health-Related Quality of LIfe Results of the Phase 2/3 Act.In.Sarc Study With Preoperative NBTXR3 Plus Radiation Therapy Versus Radiation Therapy in Locally Advanced Soft-Tissue Sarcoma
Sylvie Bonvalot et al. · International Journal of Radiation Oncology*Biology*Physics
Open access |
16 Jul 2022 |
46 |